This article has been updated from a previous version.

NEW YORK, June 13 - Celera Genomics announced its intention Wednesday to acquire Axys Pharmaceuticals in a stock transaction valued at $173.4 million, making good on its promise to purchase a company with chemistry and drug design capabilities. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.